About

Conventional chondrosarcoma is a rare bone cancer that resists chemotherapy and radiation, often recurring after surgery and spreading to the lungs. Ozekibart is an antibody designed to bind strongly to a protein called DR5 on the surface of cancer cells, which can trigger the cells to self-destruct. By directly activating this cell-death pathway, ozekibart could offer a new way to treat these tumors where other standard options have failed.